fingolimod has been researched along with Multiple Sclerosis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Black, C; Chollate, S; Guckian, KM; Hahm, K; Hetu, G; Jin, P; Kumaravel, G; Lee, WC; Lin, EY; Luo, Y; Lynch, KR; Ma, B; Macdonald, TL; Rohde, E; Rossomando, A; Scannevin, R; Scott, D; Wang, J; Yang, C | 1 |
| Oberlies, NH; Pearce, CJ; Strader, CR | 1 |
| Arnett, HA; Cee, VJ; Croghan, MD; Fiorino, M; Fotsch, C; Frohn, MJ; Harrington, PE; Horner, M; Lanman, BA; Lee, MR; McElvain, M; Morrison, HG; Pennington, LD; Pickrell, AJ; Reed, AB; Sham, KK; Tasker, AS; Wong, M; Xu, H; Xu, Y; Zhang, X | 1 |
| Beerli, C; Bergsdorf, C; Billich, A; Braendlin, N; Oberhauser, B; Schubart, A; Srinivas, H; Weiler, S | 1 |
| Akdemir, A; Dişli, A; Doyduk, D; Şen, A; Turgut, GÇ; Yavuz, S; Yıldırır, Y | 1 |
| Aronov, AM; Bandarage, UK; Cao, J; Chin, EY; Collier, PN; Come, JH; Damagnez, V; Davies, RJ; Deininger, D; Doran, JD; Dworakowski, W; Grey, R; Griffith, JP; Henderson, JA; Jacobs, MD; Khare-Pandit, S; Krueger, EB; Le Tiran, A; Liang, J; Liao, Y; Lowe, DB; Mahajan, S; Messersmith, D; Moody, CS; Nanthakumar, S; O'Dowd, H; Pierce, AC; Sizensky, E; Wang, J; Xu, J | 1 |
| Camp, SM; Garcia, JGN; Marciniak, A; Polt, R | 1 |
| Bankala, R; Doss, HM; Kapavarapu, RK; Kulkarni, P; Kumar, JS; Mathew, JE; Medishetti, R; Mudgal, J; Pal, M; Parsa, KVL; Ramarao, EVVS; Rasool, M; Shenoy, GG; Sunke, R; Thirupataiah, B | 1 |
| Bahn, YS; Cheong, E; Choi, JW; Hwang, H; Kim, B; Kim, HJ; Kim, J; Kim, JW; Kim, R; Kim, S; Kim, Y; Lee, EH; Lee, HY; Lee, J; Park, JH; Park, KD; Park, SJ; Seo, SH; Yeon, SK | 1 |
| Araldi, GL; Hwang, YW | 1 |
2 review(s) available for fingolimod and Multiple Sclerosis
| Article | Year |
|---|---|
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Topics: Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Hypocreales; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Structure-Activity Relationship; United States; United States Food and Drug Administration | 2011 |
An update on sphingosine-1-phosphate receptor 1 modulators.
Topics: Autoimmune Diseases; Biological Availability; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Oxadiazoles; Receptors, Lysosphingolipid; Sphingolipids | 2018 |
8 other study(ies) available for fingolimod and Multiple Sclerosis
| Article | Year |
|---|---|
Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.
Topics: Administration, Oral; Animals; Crystallography, X-Ray; Immunosuppressive Agents; Lymphopenia; Mice; Models, Molecular; Multiple Sclerosis; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Prodrugs; Receptors, Lysosphingolipid; Structure-Activity Relationship; Tetrahydronaphthalenes | 2010 |
Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity.
Topics: Animals; Area Under Curve; Cardiovascular Diseases; Chemistry, Physical; Drug Design; Female; Humans; Immunosuppressive Agents; In Vitro Techniques; Kinetics; Lymphocytes; Models, Chemical; Multiple Sclerosis; Quinolones; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship | 2012 |
Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis.
Topics: Administration, Oral; Aldehyde-Lyases; Animals; Catalytic Domain; Cells, Cultured; Crystallography, X-Ray; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Male; Models, Molecular; Multiple Sclerosis; Mutation; Phthalazines; Protein Conformation; Pyridines; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2014 |
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
Topics: Cell Survival; Computer-Aided Design; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Molecular Docking Simulation; Molecular Structure; Multiple Sclerosis; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase γ (PI3Kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS).
Topics: Adenosine Triphosphate; Administration, Oral; Animals; Binding Sites; Biological Availability; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Humans; Hydrogen Bonding; Isoenzymes; Mice, Inbred C57BL; Multiple Sclerosis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalimides; Structure-Activity Relationship | 2018 |
InCl
Topics: Animals; Arthritis; Cyclic Nucleotide Phosphodiesterases, Type 4; Encephalomyelitis, Autoimmune, Experimental; Freund's Adjuvant; Indium; Indoles; Molecular Structure; Multiple Sclerosis; Oligodendrocyte-Myelin Glycoprotein; Phosphodiesterase 4 Inhibitors; Quinoxalines; Rats; Structure-Activity Relationship; Zebrafish; Zebrafish Proteins | 2019 |
Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.
Topics: Animals; beta-Arrestins; Dogs; Drug Design; Encephalomyelitis, Autoimmune, Experimental; Heart Rate; Humans; Isoxazoles; Lymphocyte Count; Lymphocytes; Male; Mice; Multiple Sclerosis; Rats; Sphingosine-1-Phosphate Receptors; Structure-Activity Relationship; Triazoles | 2022 |
Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis.
Topics: Catechin; Humans; Multiple Sclerosis; Phosphorylation; Polyphenols; Structure-Activity Relationship; Tea | 2022 |